4-溴-2,6-二甲基吡啶 | 5093-70-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-溴-2,6-二甲基吡啶
• 中文别名: 2,6-二甲基-4-溴吡啶
• 英文名称: 4-bromo-2,6-dimethylpyridine
• 英文别名: 4-bromo-2,6-lutidine；4-Brom-2,6-lutidin；2,6-dimethyl-4-bromopyridine
• CAS: 5093-70-9
• 化学式: C₇H₈BrN
• 分子量: 186.051
• InChiKey: VTRFAYHJKSKHGY-UHFFFAOYSA-N

物化性质

• 熔点：
  28-32°C
• 沸点：
  194 °C
• 密度：
  1.415±0.06 g/cm3(Predicted)
• 闪点：
  93℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S24/25,S26,S39
• 危险类别码：
  R22,R41,R37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险品运输编号：
  NONH for all modes of transport
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H315,H318,H335
• 危险性防范说明：
  P261,P280,P305 + P351 + P338
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2,6-dimethylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2,6-dimethylpyridine
CAS number: 5093-70-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8BrN
Molecular weight: 186.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-溴-2,6-二甲基吡啶及其同系物存在于骨焦油、煤焦油、煤气、页岩油和石油中。在工业上，它可用作变性剂、助染剂，并作为合成一系列产品（包括药品、消毒剂和染料等）的原料。

合成方法

将2,6-二甲基吡啶-4-醇（3.25 g）溶解于氯仿（40 mL）中，加入五溴化磷（11.5 g），然后加热至60°C反应2小时。去除溶剂后，将残留物加热至120°C过夜。用45 g NaOH（溶解在500 mL水中）处理反应混合物，并用乙酸乙酯（EtOAc，3 x 100 mL）萃取产物。结合的有机物经过硫酸钠干燥并浓缩到硅藻土上。通过硅胶色谱法使用己烷中的乙酸乙酯进行纯化（0-35%），得到黄色油状物质，产量为2.95克。


健康危害

4-溴-2,6-二甲基吡啶具有强烈刺激性，能麻醉中枢神经系统。它对眼睛和上呼吸道有刺激作用。高浓度吸入后，轻者可能出现欣快或窒息感，继之出现抑郁、肌无力和呕吐；重者可能导致意识丧失、大小便失禁、强直性痉挛、血压下降甚至死亡。误服可致死。

反应信息

• 作为反应物：
  描述：

  4-溴-2,6-二甲基吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 14.0h， 生成 2,6-dimethyl-4-(4-nitrophenyl)pyridine
  参考文献：
  名称：

  [EN] BICYCLIC KINASE INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE KINASE BICYCLIQUES ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2021219731A3
• 作为产物：
  描述：

  脱氢乙酸 在 ammonium hydroxide 、 五溴化磷 、 三溴氧磷 作用下， 以 氯仿 为溶剂， 反应 15.0h， 生成 4-溴-2,6-二甲基吡啶
  参考文献：
  名称：

  Takalo, Harri; Pasanen, Paavo; Kankare, Jouko, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1988, vol. 42, # 6, p. 373 - 377

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-硝基苯硫醇 在 4-溴-2,6-二甲基吡啶 、 copper(l) iodide 、 三氟甲苯 、 三氟化硼乙醚 、 C₂₆H₄₃FeO₃⁽¹⁺⁾*BF₄^(1-) 、 potassium carbonate 、 二异丙胺 、 potassium iodide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 74.0h， 生成 N-(1-(4-chlorophenyl)-5-((4-nitrophenyl)thio)-2-vinylidenepentyl)-N,2,4,6-tetramethylbenzenesulfonamide
  参考文献：
  名称：

  铁催化的丙二烯 C(sp2)-H 键的对比官能化：α-氨基烷基 1,1-二取代的丙二烯的合成

  摘要：

  报道了简单的单取代丙二烯的铁催化 C-H 官能化。通过使用新开发的富电子和空间位阻阳离子环戊二烯基二羰基络合物作为催化剂和N-磺酰基半胺基醚试剂作为亚胺离子亲电试剂的前体，使该过程的有效方案成为可能。在优化条件下，使用温和的、官能团耐受的碱基能够将一系列单烷基丙二烯转化为其烯属磺酰胺基 1,1-二取代衍生物，这是以前未报道的、对比鲜明的 C-H 官能化区域化学结果。电子无偏和无导向基团的丙二烯。

  DOI：

  10.1021/jacs.1c07512

文献信息

• [EN] SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO<br/>[FR] COMPOSÉS PYRAZOLE ET PYRROLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CES DERNIERS POUR L'INHIBITION DE L'INITIATION DE LA TRADUCTION ET LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À CETTE DERNIÈRE
  申请人：BANTAM PHARMACEUTICAL LLC

  公开号：WO2016196644A1

  公开（公告）日：2016-12-08

  Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

  揭示了吡唑化合物，以及其药物组合物和使用方法。其中一种实施例是具有结构（I）及其药用可接受的盐和/或氧化物，其中X1、X2、Z1、Z2、由“a”表示的环系统、R1、A1A、L1B、A1B、L1A、L2、Q、L3、R3、A4A、L4B、A4B、L4A、R4、L5和R5如本文所述。在某些实施例中，本文所披露的化合物破坏elF4E/eiF4G相互作用，并可用于治疗过度增殖性疾病、神经系统疾病或障碍，或自闭症。
• INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：ECKHARDT Matthias

  公开号：US20140163025A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R 1 are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物， 其中基团(Het)Ar和R1如权利要求1所定义， 具有有价值的药理特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123291A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性核瘫痪；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病、帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍）、带有Lewy小体的痴呆、多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• [EN] METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES NÉGATIFS (NAM) DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE ET UTILISATIONS DE CEUX-CI
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2015191630A1

  公开（公告）日：2015-12-17

  Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

  本文提供了小分子活性代谢型谷氨酸亚型-2和-3受体负向变构调节剂（NAMs），包括这些化合物的组合物，以及使用这些化合物和组合物的方法。
• 吡啶类N-氧化衍生物及其制备方法和应用
  申请人：上海翰森生物医药科技有限公司

  公开号：CN110041253B

  公开（公告）日：2022-03-29

  本发明涉及吡啶类N‑氧化衍生物及其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为BRD4抑制剂在治疗癌症、炎症、慢性肝病、糖尿病、心血管疾病和AIDS等相关疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。